欧盟HMA药品数据库(European Union HMA Authorisation of Medicines DataBase)
MR编号
NL/H/0144/004
药品名称
Maxalt Smelt 10 mg
活性成分
rizatriptan (as benzoate) 10.0 mg
剂型
Oral lyophilisate
上市许可持有人
N.V. Organon Kloosterstraat 6 5349 AB Oss The Netherlands
参考成员国 - 产品名称
Netherlands (NL)
互认成员国 - 产品名称
Iceland (IS)
Ireland (IE)
Norway (NO)
Lithuania (LT)
MAXALT 10mg geriamasis liofilizatas
Romania (RO)
Maxalt 10 mg liofilizat oral
Germany (DE)
Denmark (DK)
Belgium (BE)
Luxembourg (LU)
United Kingdom (Northern Ireland) (XI)
Austria (AT)
Maxalt Rapitab 10 mg
France (FR)
Spain (ES)
Italy (IT)
Greece (GR)
Sweden (SE)
Finland (FI)
许可日期
1998/06/09
最近更新日期
2024/12/18
药物ATC编码
N02CC04 rizatriptan
申请类型
TypeLevel1:
[not specified]
TypeLevel2:
[not specified]
TypeLevel3:
Full Dossier Article 4.8 Di 65/65
TypeLevel4:
[not specified]
TypeLevel5:
[not specified]
附件文件下载
Final PL
|
common_PIL_combined
Date of last change:2024/09/06
Final Product Information
|
Final combined PI MAXALT_NL_H_0144_001_004_IA_082_PI_EU_en_CRT
Date of last change:2024/09/06
Final SPC
|
Final day 120 PI _MAXALT_NL_H_0144_II_043 clean version
Date of last change:2024/09/06
市场状态
Positive
©2006-2025
Drugfuture
->
European Union HMA Authorisation of Medicines DataBase